Bioconjugation Fundamentals and SoluLINK Technology Webinar

Added:

The Paradigm Shift to Site-Specific Bioconjugation

While traditional bioconjugation technologies like SoluLINK rely on chemical modification of native lysine or cysteine residues, these methods often produce heterogeneous mixtures. Because proteins contain multiple reactive residues, the resulting conjugates suffer from variable drug-to-antibody ratios (DAR) and potential disruption of the protein’s active site. In contrast, the modern paradigm of site-specific conjugation—utilizing enzymatic methods (such as sortase-mediated ligation) or genetic code expansion to incorporate unnatural amino acids—offers a highly precise alternative. This approach ensures that conjugates are homogeneous, with exact stoichiometry and preserved biological activity, directly addressing the structural heterogeneity and reproducibility limitations of traditional chemical conjugation methods.

Basic protein structure and biochemistry, particularly the properties of reactive amino acid side chains like lysine and cysteine.
Fundamentals of organic chemistry, including covalent bond formation, nucleophilic substitution, and active ester chemistry (e.g., NHS-esters).
The basic structure and function of antibodies (immunoglobulins), including variable and constant domains.
Standard laboratory methods for protein purification and separation, such as size-exclusion chromatography and dialysis.
Design and development of Antibody-Drug Conjugates (ADCs) for targeted cancer therapies.
Advanced bioorthogonal chemistry methods, such as copper-free click chemistry and strain-promoted azide-alkyne cycloaddition (SPAAC).
Analytical techniques for characterization of bioconjugates, including Mass Spectrometry (LC-MS) to determine the Drug-to-Antibody Ratio (DAR).
Application of custom conjugates in advanced assay development, such as multiplexed ELISA, flow cytometry, and Western blotting.
8.9K views186likes1:00:38@vectorlaboratoriesOriginal Release: 2022-05-31

Bioconjugation is the chemical linking of two molecules to form a single hybrid unit, where at least one component is a biomolecule such as an antibody, peptide, protein, or oligonucleotide. The process involves targeting functional groups (such as amines, sulfhydryls, or aldehydes) on biomolecules using bifunctional linkers—either homo-bifunctional (same reactive groups on both ends) or hetero-bifunctional (different reactive groups)—to create bioconjugates that retain the activity of each original component while providing additional functionality. Key considerations for successful bioconjugation include determining the intended application, selecting appropriate reactive groups based on biomolecule accessibility, choosing appropriate spacer arms, ensuring solubility and stability, and removing unincorporated label. Applications range from antibody-drug conjugates for targeted cancer therapy to multiplex immunofluorescence and DNA-barcoded antibody arrays for high-throughput protein detection.